Aster DM Healthcare Limited — Q3 FY25 earnings call

Call held 3 Feb 2025

Management summary

Aster DM Health delivered a strong 9M FY25 performance characterized by significant margin expansion and robust ARPOB growth. The company is undergoing a transformative merger with QCIL to become one of India's largest healthcare providers while simultaneously executing an aggressive brownfield expansion plan. Management remains focused on high-end specialty mix (Oncology/Neuro) and operational efficiencies to drive consolidated margins toward a 21% target by FY27.

Highlights

  • 9M FY25 Revenue grew 15% YoY to ₹3,138 crore, driven by a 12% increase in ARPOB.

  • Operating EBITDA for 9M FY25 rose 35% to ₹613 crore, with margins expanding 290bps to 19.5%.

  • Adjusted Net Profit (excluding merger costs) surged 65% YoY to ₹251 crore for the 9M period.

  • Hospital segment EBITDA margins improved to 22.3% in 9M FY25; mature hospitals reached 25% margin.

  • Strategic merger with QCIL (CARE Hospitals) approved by 99.99% of shareholders, creating a top 3 Indian hospital chain with 10,000+ beds.

  • Capacity expansion on track with ~1,700 beds to be added by FY27, taking total capacity to 6,800+ beds.

  • Aster Labs achieved a positive EBITDA margin of 8% in 9M FY25 after breaking even in Q4 FY24.

  • Net cash position remains strong at ₹1,014 crore as of December 31, 2024.

Key financials

  1. Revenue ₹3,138 Cr +15%YoY
  2. Operating EBITDA ₹613 Cr +35%YoY
  3. EBITDA Margin 19.5%
  4. Adjusted Net Profit ₹251 Cr +65%YoY
  5. ARPOB Growth 12% +12%YoY
  6. Net Cash ₹1,014 Cr

What they filed

Q1 FY27: revenue up 21.6%, net profit down 69.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,086 1,050 1,000 1,078 1,197 +10%1,186 +13%1,182 +18%1,311 +22%
EBITDA217 186 182 202 236 +9%202 +9%224 +23%256 +27%
Net profit106 64 86 94 121 +14%59 −8%154 +79%29 −69%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹3,020 Cr Total
  • Kerala Cluster ₹1,609 Cr 53.3%
  • Karnataka & Maharashtra Cluster ₹1,054 Cr 34.9%
  • Andhra & Telangana Cluster ₹357 Cr 11.8%

Guidance & targets

Capacity

  • Total Bed Capacity Capacity · FY27 · High confidence 6,800+

    From 5,128 today

    Looking ahead, we plan to add approximately 1,700 beds, increasing our total capacity to over 6,800 beds by FY27.

    — Alisha Moopen, Deputy Managing Director

Margin

  • Consolidated India EBITDA Margin Margin · FY26-27 · Medium confidence 21%

    From 19.5% today

    I expect that by FY26 - 27, we should be somewhere near 21%.

    — Sunil Kumar M R, CFO

  • Hospital & Clinic Segment Margin Margin · FY27 · Medium confidence 24%

    From 22.3% today

    And from the hospital clinic segment, which we are today at 22.3 - 22.4%, there you can expect around 24% margin.

    — Sunil Kumar M R, CFO

Capex

  • Expansion Capex Capex · next 3 years · High confidence ₹1,100 crores
    for example, the 1700 beds, which is in pipeline as on 31st December 2024, we need approximately INR 1,100 crores for a period of three years.

    — Sunil Kumar M R, CFO

Other

  • Solar Power Savings Other · FY26 · High confidence ₹15-16 crores
    a 26-megawatt plant is work in progress in Kerala. That should give more than 15 to 16 crores worth of savings in the coming year.

    — Sunil Kumar M R, CFO

Profitability

  • Pharmacy Breakeven Profitability · Q4 FY26 · Medium confidence Breakeven
    we're expecting to break even sometime in the last quarter of FY26.

    — Sunil Kumar M R, CFO

Risks & concerns

  • Increased Competition in Kerala

    medium

    Analysts noted a competitor entering Kerala with ~3,000 beds; management believes their legacy and clinical quality provide a moat.

    Analyst downplayed

  • MVT (Medical Value Travel) Slowdown

    medium

    Reduction in footfalls from Maldives and GCC impacted Kerala cluster performance in Q3.

    Management acknowledged

  • Material Cost Volatility

    low

    Shift toward high-end specialties like Oncology increases material costs, which rose ~100bps QoQ.

    Management acknowledged

Areas of evasion (2)

  • Refused to share CARE Hospitals' performance data due to pending CCI approvals.
  • Avoided giving specific pro-forma joint financials for the merged entity.

Q&A highlights

3 direct
Kerala Cluster Growth Slowdown Direct
the flu season actually ended in Q2. So, definitely there has been a footfall difference we're seeing quarter-on-quarter... from an MVT perspective also, there has been some reduction in the footfalls from both GCC as well as Maldives.

Explains the temporary nature of the growth dip in the flagship Kerala cluster due to seasonality and international patient mix.

Asked by Amey

Margin Compression in Q3 vs Q2 Direct
whenever oncology is taking the front in driving the growth, usually we see that the material cost takes impact. That's why almost near to 1% the material cost also has increased between Q2 and Q3, FY25.

Reveals the trade-off between high-ARPOB specialty growth (Oncology) and higher material costs, impacting short-term margins.

Asked by Bino

Competitive Threat in Kerala Direct
Kerala has always been a price sensitive market, and we are already having a legacy there... anyone who is coming in, they will be forced... to increase the prices or which in turn again will raise the ARPOB. We see that competition is not going to affect Aster in any way.

Management signals they will not engage in price wars with new entrants (3,000 beds expected) and will rely on brand legacy and high-end clinical work.

Asked by Kunal / Prolin

2 min read 5 chapters

Detailed narrative

Strategic Merger to Create Top-Tier Hospital Chain

Aster DM Healthcare is in the final stages of merging with Blackstone-backed Quality Care India Limited (QCIL), which includes CARE Hospitals and KIMSHEALTH. The merger received overwhelming shareholder approval with 99.99% votes in favor and is currently awaiting CCI and NCLT approvals. The combined entity will operate 38 hospitals with over 10,000 beds, positioning it as one of the top three hospital chains in India. Management expects the merger to drive significant synergies in procurement, corporate costs, and geographic reach across nine Indian states.

Aggressive Brownfield Expansion Strategy

The company is executing a robust expansion plan to add approximately 1,700 beds by FY27, increasing total capacity to over 6,800 beds. Major brownfield projects are underway at Aster Medcity (950 beds total), Aster CMI (850 beds), and Aster Whitefield (500 beds). In the current year, 271 beds have already been added. Crucially, management stated that this ₹1,100 crore expansion will be funded through internal accruals and existing cash flows, maintaining a net-cash positive balance sheet without additional debt.

Operational Efficiency and Margin Trajectory

Operating EBITDA margins for the India business expanded to 19.5% in 9M FY25, up from 16.6% a year ago. This was driven by a 12% increase in ARPOB and a reduction in material costs (excluding wholesale pharmacy) to 20.7%. Mature hospitals (6+ years) are already operating at a 25% EBITDA margin with a 36% ROCE. Management has set a target to reach a consolidated margin of 21% by FY27, supported by the ramp-up of newer hospitals like Whitefield and the breakeven of the pharmacy business by Q4 FY26.

Cluster Performance and Specialty Mix

The Karnataka and Maharashtra cluster showed the strongest growth at 33% YoY, reaching ₹1,054 crore in 9M FY25, with margins improving to 23.2%. The Kerala cluster, while seeing slightly muted growth due to seasonal flu timing and MVT shifts, remains the largest contributor with ₹1,609 crore revenue and 23.7% margins. The company is intentionally shifting its case mix toward high-end specialties like Oncology (up 28%), Cardiac (up 16%), and Neuro (up 19%), which is driving ARPOB higher despite slightly increasing material costs.

New Business Verticals Turn Profitable

Aster Labs has successfully turned around, achieving a positive EBITDA margin of 8% in 9M FY25 after breaking even in Q4 FY24. External (non-Aster) business now accounts for 28-30% of lab revenue, up from ~22% last year, with a target to grow this segment by 35-40% in the coming year. The pharmacy business, currently operating 203 retail stores, is undergoing a consolidation phase to limit cash burn and is expected to reach breakeven by the end of FY26.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls